Ralliant (NYSE:RAL) Price Target Raised to $73.00 at Royal Bank Of Canada

Ralliant (NYSE:RAL) had its target price hoisted by Royal Bank Of Canada from $71.00 to $73.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has a “sector perform” rating on the stock. Royal Bank Of Canada’s price objective would suggest a potential upside of 9.53% from the stock’s current price.

A number of other brokerages have also commented on RAL. BMO Capital Markets assumed coverage on shares of Ralliant in a research note on Monday, July 20th. They issued a “market perform” rating and a $78.00 price target on the stock. Oppenheimer raised their price objective on shares of Ralliant from $50.00 to $65.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 13th. Evercore assumed coverage on Ralliant in a report on Tuesday, June 9th. They set an “outperform” rating and a $80.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Ralliant in a research report on Monday, May 4th. Finally, Barclays increased their target price on Ralliant from $52.00 to $67.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 13th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Ralliant presently has an average rating of “Moderate Buy” and a consensus price target of $75.60.

Ralliant Stock Performance

Shares of NYSE:RAL traded down $0.35 on Friday, hitting $66.65. The company had a trading volume of 1,223,872 shares, compared to its average volume of 1,711,941. Ralliant has a 1-year low of $37.27 and a 1-year high of $75.41. The stock has a market cap of $7.46 billion and a price-to-earnings ratio of -6.09. The stock has a 50 day moving average price of $67.12 and a 200 day moving average price of $54.26. The company has a current ratio of 1.61, a quick ratio of 1.05 and a debt-to-equity ratio of 0.73.

Ralliant (NYSE:RAL) last issued its quarterly earnings data on Thursday, July 30th. The company reported $0.68 earnings per share for the quarter, beating the consensus estimate of $0.63 by $0.05. The company had revenue of $567.80 million for the quarter. Ralliant had a negative net margin of 58.55% and a positive return on equity of 12.49%. Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. Analysts expect that Ralliant will post 2.64 EPS for the current year.

Institutional Trading of Ralliant

A number of institutional investors have recently bought and sold shares of RAL. Allworth Financial LP boosted its stake in shares of Ralliant by 134.4% in the fourth quarter. Allworth Financial LP now owns 511 shares of the company’s stock valued at $26,000 after buying an additional 293 shares during the period. Rothschild Investment LLC raised its holdings in Ralliant by 98.1% in the 4th quarter. Rothschild Investment LLC now owns 612 shares of the company’s stock valued at $31,000 after acquiring an additional 303 shares in the last quarter. Keybank National Association OH raised its holdings in Ralliant by 1.6% in the 4th quarter. Keybank National Association OH now owns 19,667 shares of the company’s stock valued at $1,001,000 after acquiring an additional 305 shares in the last quarter. UMB Bank n.a. lifted its position in shares of Ralliant by 49.6% during the 4th quarter. UMB Bank n.a. now owns 983 shares of the company’s stock valued at $50,000 after acquiring an additional 326 shares during the period. Finally, Maryland State Retirement & Pension System grew its holdings in shares of Ralliant by 1.5% during the 4th quarter. Maryland State Retirement & Pension System now owns 21,940 shares of the company’s stock worth $1,117,000 after purchasing an additional 329 shares in the last quarter.

Key Headlines Impacting Ralliant

Here are the key news stories impacting Ralliant this week:

• Positive Sentiment: Truist raised its price target: Truist Financial reaffirmed its “buy” rating and increased its target to $82 from $68, implying substantial upside from the current trading level. Benzinga
• Positive Sentiment: Second-quarter earnings beat expectations: Ralliant reported adjusted EPS of $0.68, ahead of the $0.63 consensus estimate and slightly above $0.67 a year earlier. Revenue reached approximately $568 million, up 13% year over year on both a reported and organic basis. Net earnings were $57 million, while adjusted net earnings were $76 million. Ralliant Reports Second Quarter 2026 Results and Raises Full Year Guidance
• Positive Sentiment: Management raised its outlook: Ralliant’s third-quarter guidance calls for adjusted EPS of $0.72–$0.78 and revenue of $570–$590 million, both above consensus estimates. Full-year adjusted EPS guidance increased to $2.76–$2.90 from an analyst estimate of $2.65, with projected revenue of roughly $2.25–$2.30 billion. Ralliant 2026 Revenue Forecast and Productivity Program
• Positive Sentiment: Cost savings could support future margins: The company’s enterprise productivity program targets $50 million–$60 million in annualized savings by 2028, adding a potential longer-term earnings catalyst.
• Neutral Sentiment: Trading in RAL was temporarily paused on July 30 under a limit-up/limit-down (LULD) volatility halt. The reports do not identify a company-specific negative catalyst behind the subsequent weakness.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.